HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J no liability

This article was originally published in The Tan Sheet

Executive Summary

A California jury cleared McNeil Consumer & Specialty Pharmaceuticals on July 17 of liability in a lawsuit filed by 11-year-old Sabrina Brierton Johnson, who suffered Stevens-Johnson syndrome after using Children's Motrin. Johnson, who is now blind, will appeal her case, which alleges the Johnson & Johnson division failed to adequately warn on its product label that the ibuprofen in Motrin can trigger a rare allergic reaction that causes blindness and even death, according to lawyers at Greene Broillet & Wheeler, which represented the girl and her parents in the case litigated in Los Angeles Superior Court ("The Tan Sheet" June 16, 2008, p. 9)...

You may also be interested in...



Children’s Motrin Suit Seeks Compensation, New Label For Ibuprofen Product

A lawsuit that alleges Children's Motrin with ibuprofen caused a girl's blindness wants McNeil Consumer & Specialty Pharmaceuticals to clearly list all potential serious adverse reactions on the product's label and compensate the child

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel